Investors are monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor, Guenther Koehne ...

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted upcoming clinical milestones for the company’s two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Pillar Biosciences today announced the launch of the oncoReveal® Rapid AML Panel, a focused research-use-only (RUO) DNA ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

The study, titled “Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” was recently published in Blood and focuses on acute myeloid ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...